Senseonics Holdings stock fell 3.39 percent on October 6

Published on 10/07/2026 at 02:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Senseonics Holdings stock carries a Moderate Buy consensus from six analysts with a USD 17.20 average target. Q2 revenue reached USD 14.48 million, up from USD 6.65 million.

SENS, US81727U3032, Illustration mit AI erstellt.

Senseonics Holdings, Inc. (ISIN US81727U3032) was last at USD 9.96 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 3.39 percent from the prior close. The latest reported quarter combined rapid revenue growth with a wider loss, giving the stock a sharply divided operating picture.

Revenue doubled in Q2

According to Markets Insider, Senseonics generated USD 14.48 million in revenue for the quarter ended June 30, 2026, versus USD 6.65 million in the second quarter of 2025. That represents an increase of 117.7 percent, while the GAAP net loss widened to USD 36.71 million from USD 14.5 million.

The earnings comparison matters because revenue expansion has not yet translated into profitability. The same June 30, 2026 report showed a GAAP loss of USD 0.63 per share, compared with a USD 0.36 loss a year earlier.

Analysts see a higher target

According to MarketBeat on October 1, 2026, six analysts held a Moderate Buy consensus: four Buy ratings, one Hold and one Sell. Their average 12-month price target was USD 17.20, which lies 72.7 percent above the USD 9.96 price.

The target spread also shows why the consensus is not a uniform signal. MarketBeat reported that Mizuho cut its target from USD 20.00 to USD 18.00 on July 15, 2026, while maintaining an Outperform rating.

Q4 integration sets a milestone

Senseonics announced on September 14, 2026, that it would integrate its Eversense 365 continuous glucose monitor with Beta Bionics' iLet Bionic Pancreas. The company plans to complete development and pursue a commercial launch in Q4 2026, subject to testing, validation and regulatory requirements.

The product milestone gives the growth story a concrete timetable. Eversense 365 is designed for one year of continuous glucose monitoring, while the iLet system automates insulin delivery without requiring carbohydrate counting.

Stock remains below yearly high

Senseonics Holdings stock was last at USD 9.96 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a market capitalization of USD 416.3 million; its 52-week range was USD 4.79 to USD 10.64.